

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



Scan this QR to view the Prospectus

BIOPOL CHEMICALS LIMITED

Corporate Identification Number: U20297GJ2023PLC140117

Our Company was originally incorporated on April 12, 2023 under the name "Biopol Chemicals Private Limited" under the provisions of the Companies Act, 2013 with the Registrar of Companies, Central Registration Centre. Subsequently, our Company acquired the sole proprietorship firm of Mr. Santanu Sarkar i.e. "M/s. United Chemical Company", pursuant to a Business Takeover Agreement dated September 25, 2023, effective from September 30, 2023. Thereafter, the status of the Company was changed to public limited Company and the name of our Company was changed to "Biopol Chemicals Limited" vide Special Resolution passed by the Shareholders at the Extra-Ordinary General Meeting of our Company held on February 22, 2024. The fresh certificate of incorporation consequent to conversion was issued on May 16, 2024 by Registrar of Companies, Central Registration Centre. The Corporate Identification Number of our Company is U20297GJ2023PLC140117. For further details on Incorporation and Registered Office of our Company, see "History and Certain Corporate Matters" beginning on page 175 of the Prospectus.

Registered Office: D-211, 2nd Floor, Block-D, Sumel Bu, Nr Dudheshwar Circle, Dudheshwar Tavdipura, Ahmedabad, Ahmadabad City - 380004 Gujarat, India;

Corporate Office: Unit No 2ES3B1, 2nd Floor Mani Casadona Street No 372 Action Area 1, IIF Newtown Alia University, New town, North 24 Parganas, West Bengal-700156, India

Tel No: +91- 9147076778 | E-mail: investors@biopolchemicals.com | Website: https://biopolchemicals.com/;

Contact Person: Ms. Deepti Nama, Company Secretary and Compliance Officer

THE PROMOTERS OF OUR COMPANY ARE MR. SANTANU SARKAR AND MR. VEDANT SARKAR

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE (NSE EMERGE)."

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 28,94,400 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH (THE "EQUITY SHARES") OF BIOPOL CHEMICALS LIMITED ("OUR COMPANY" OR "BIOPOL" OR "THE ISSUER") FOR CASH AT A PRICE OF ₹108/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹98/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹3,125.95 LAKHS ("THE ISSUE"), OF WHICH 1,51,200 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹108/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹98/- PER EQUITY SHARE AGGREGATING TO ₹163.30 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e., NET ISSUE OF 27,43,200 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹108/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹98/- PER EQUITY SHARE AGGREGATING TO ₹2,962.66 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.79 % AND 25.39 % RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION - Not Applicable as the entire issue constitutes fresh issue of equity shares.

ISSUE PRICE: ₹ 108.00 PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH.
THE ISSUE PRICE IS 10.80 TIMES OF THE FACE VALUE

BID/ISSUE PROGRAMM

BID/ISSUE OPENED ON: FRIDAY, FEBRUARY 06, 2026

BID/ISSUE CLOSED ON: TUESDAY, FEBRUARY 10, 2026

RISKS TO INVESTORS

- Risk to investors: Top 5 Risk factors:**
 - Our speciality chemicals are used in the textile segment and our business is significantly dependent on the textile industry. Any adverse developments in that industry may materially and adversely affect our business, financial condition, results of operations and cash flows.
 - A significant portion of our revenue is derived from customers located in West Bengal, Gujarat and Bangladesh. Any adverse developments in these regions may materially and adversely affect our business, financial condition, results of operations and cash flows.
 - The Company is dependent on a limited number of suppliers for the procurement of critical raw materials. The loss of any of these suppliers or disruption in supply may materially and adversely affect our business operations, financial condition, results of operations and cash flows.
 - Our revenue is derived through a combination of direct sales and distributor-driven sales, and any disruption or inefficiency in either channel may materially and adversely affect our business, financial condition, results of operations and cash flows. Additionally, we do not have long-term agreements with certain distributors, which exposes us to the risk of losing them or facing unfavourable commercial terms.
 - Our expansion plans, including the acquisition of industrial land in Gujarat, may expose us to operational, regulatory, and execution risks, and any delay or inability to complete the project as envisaged could adversely affect our business, results of operations, and financial condition.
- Our Equity Shares have never been publicly traded and may experience price and volume fluctuations following the completion of the Issue. Further, our Equity Shares may not result in an active or liquid market, and the price of our Equity Shares may be volatile, and you may be unable to resell your Equity Shares at or above the Issue Price or at all.
- The Merchant Banker associated with the Issue has handled following public issues in the past three years which have closed below the Issue Price on Listing date:

Name of Lead Manager	Total Issues	Issues that closed below IPO price as on listing date
Smart Horizon Capital Advisors Private Limited	19	03
Total	19	03

4. The average cost of acquisition of Equity Shares by our Promoters is as follows:

Name of Promoters	No. of Equity Shares held	Average cost of Acquisition (in ₹)*
Mr. Santanu Sarkar	69,30,500	4.73
Mr. Vedant Sarkar	1,80,000	11.11
Name of Promoter Group		
NA	NA	NA

*As certified by our Auditors, by way of their certificate dated January 16, 2026.

5. Weighted average cost of acquisition:

The weighted average cost of acquisition of Equity Shares as compared with the Price Band is set forth below*:

Type of Transactions	Weighted average cost of acquisition (₹ per Equity Share)*	Floor Price (₹ 102/-)	Cap Price (₹ 108/-)
Weighted average cost of acquisition of primary issuances	NA	NA	NA
Weighted average cost of acquisition for secondary transactions	29.00	3.52	3.72

*As certified by our Auditors, by way of their certificate dated February 11, 2026.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 (1) and 253 (2) of the SEBI ICDR Regulations 2018, wherein 6,86,400 Equity Shares being not more than 50.00% of the Net Issue was available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"). Further, 5.00% of the Net QIB Portion was available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion was available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, the SEBI ICDR Regulations 2018, states that not less than 35% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size. Not less than 15% of the Net Issue shall be available for allocation to Non-Institutional Investors of which one-third of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than two lots and up to such lots as equivalent to not more than ₹ 10.00 Lakhs and two-thirds of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than ₹ 10.00 Lakhs and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion. Subject to the availability of shares in non-institutional investors' category, the allotment to each Non-Institutional Investors shall not be less than the minimum application size in Non-Institutional Category and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule XIII of the SEBI (ICDR) Regulations, 2018. All Potential Bidders, other than Anchor Investors, are required to participate in the Issue by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self-Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, please refer to the chapter titled "Issue Procedure" on page 315 of the Prospectus.

No allotment done in Anchor portion.

The Issue was subscribed to the extent of 24.26 times (excluding the Anchor Investor Portion) as per the bid books of NSE (the "Bid Files") after removing multiple and duplicate bids.

The issue received 12,300 applications for 6,14,86,800 Equity Shares before technical rejections and after invalid bids Multiple/Duplicate/bids, UPI Mandates not accepted by investors, bids rejected under application banked but did not registered resulting in 21.24 times subscription (including reserved portion of market maker).

Detail of the Applications Received:

The Details of the Applications received from various categories (before technical rejection) are as under:

Sr. No.	Category	Number of Applications	No. of Equity Shares Applied	Equity Shares Reserved as per Prospectus	No. of times Subscribed	Amount (₹)
1	Individual Investors	8,359	2,00,61,600	9,62,400	20.85	2,16,61,65,600
2	Non-Institutional Bidders 1 (More than 2 lots & up to ₹10,00,000/-)	1,854	67,64,400	3,64,800	18.54	73,05,55,200
3	Non-Institutional Bidders 2 (More than ₹10,00,000/-)	2,072	2,00,83,200	7,29,600	27.53	2,16,89,85,600
4	Qualified Institutional Buyers (excluding Anchor Portion)	14	1,44,26,400	6,86,400	21.02	1,55,80,51,200
5	Market Maker	1	1,51,200	1,51,200	1.00	1,63,29,600
	Total	12,300	6,14,86,800	28,94,400	21.24	6,64,00,87,200

Final Demand

A summary of the final demand as per NSE as on the Bid/Issue Closing Date at different Bid Prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% of Total	Cumulative Share Total	Cumulative % of Total
1	102.00	2,01,600	0.29	2,01,600	0.29
2	103.00	24,000	0.03	2,25,600	0.32
3	104.00	21,600	0.03	2,47,200	0.35
4	105.00	46,800	0.07	2,94,000	0.42
5	106.00	48,000	0.07	3,42,000	0.48
6	107.00	37,200	0.05	3,79,200	0.54
7	108.00	7,01,65,400	99.46	7,05,45,600	100.00
	Total	7,05,45,600	100.00		100.00

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange – NSE on February 11, 2026.

- Allocation to individual investors who applies for minimum application size (After Technical Rejections):** The Basis of Allotment to individual investors who applies for minimum application size, who have bid at cut-off Price or at or above the Issue Price of ₹108.00 per equity shares, was finalized in consultation with NSE. The category was subscribed by 20.63 times i.e., for 1,98,57,600 Equity Shares. Total number of shares allotted in this category is 9,62,400 Equity Shares to 401 successful applicants. The category wise details of the Basis of Allotment are as under:

No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in this category	% of Total	Proportionate Shares available	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Number of successful applicants (after rounding)	Total No. of shares allocated/ allotted
2,400	8,274	100.00	1,98,57,600	100.00	9,62,400	2,400	401:8274	401	9,62,400
Total	8,274	100.00	1,98,57,600	100.00	9,62,400			401	9,62,400

- Allocation to Non-Institutional Investors Nil 1 Category (More than 2 lots & up to ₹10,00,000/-) (After Technical Rejections):** The Basis of Allotment to Other than Individual Investors to Non-Institutional Investors Nil 1 Category, who have bid at Issue Price of ₹ 108.00 per equity shares or above, was finalized in consultation with NSE. The category was subscribed by 18.38 times i.e., for 67,03,200 shares. The total number of shares allotted in this category is 3,64,800 Equity Shares to 101 successful applicants. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in each category	% of Total	No. of Equity Shares allocated/ allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	3,600	1809	98.48	65,12,400	97.15	3,600	100:1809	3,60,000
2	4,800	9	0.49	43,200	0.64	3,600	0:9	0
3	6,000	2	0.11	12,000	0.18	3,600	0:2	0
4	7,200	6	0.33	43,200	0.64	3,600	0:6	0
5	8,400	11	0.60	92,400	1.38	3,600	1:11	3,600
6	1,200 Additional share will be allotted to successful allottees from Sr no. 2 to 5 = 1200 shares in ratio of 1:1							
	Total	1837	100.00	67,03,200	100.00			3,64,800

- Allocation to Non-Institutional Investors Nil 2 Category (More than ₹ 10,00,000/-) (After Technical Rejections):** The Basis of Allotment to Other than Individual Investors to Non-Institutional Investors Nil 2 Category, who have bid at Issue Price of ₹108.00 per equity shares or above, was finalized in consultation with NSE. The category was subscribed by 27.51 times i.e., for 2,00,73,600 shares. The total number of shares allotted in this category is 7,29,600 Equity Shares to 202 successful applicants. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in each category	% of Total	No. of Equity Shares allocated/ allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	9,600	2060	99.47	1,97,76,000	98.52	3,600	201:2060	7,23,600
2	10,800	9	0.43	97,200	0.48	3,600	1:9	3,600
3	15,600	1	0.05	15,600	0.08	3,600	0:1	0
4	1,84,800	1	0.05	1,84,800	0.92	3,600	0:1	0
5	2,400 Additional share will be allotted to successful allottees from Sr no. 1 to 4 = 1200 shares in ratio of 2:202							
	Total	2,071	100.00	2,00,73,600	100.00			7,29,600

- Allocation to QIBs excluding Anchor Investors (After Technical Rejections):** The Basis of Allotment to QIBs, who have bid at Issue Price of ₹108.00 per equity shares or above, was finalized in consultation with NSE. The category was subscribed by 21.02 times i.e., for 1,44,26,400 shares the total number of shares allotted in this category is 6,86,400 Equity Shares to 13 successful applicants. The category wise details of the Basis of Allotment are as under:

Category	FIS/BANK'S	MFS	IC'S	NBFC'S	AIF	FPC/FII	Others	Total
QIB	-	-	-	2,60,400	4,26,000	-	-	6,86,400

- Allocation to Market Maker (After Technical Rejections):** The Basis of Allotment to Market Maker, who have bid at Issue Price of ₹108.00/- per equity shares or above, was finalized in consultation with NSE. The category was subscribed by 1.00 time i.e., for 1,51,200 shares the total number of shares allotted in this category is 1,51,200 Equity Shares. The category wise details of the Basis of Allotment are as under:

No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in this category	% of Total	No. of Equity Shares allocated/ allotted per Applicant	Ratio	Total Number of shares allotted	Surplus/Deficit
1,51,200	1	100.00	1,51,200	100.00	1,51,200	1:1	1,51,200	0.00
Total	1	100	1,51,200	100	1,51,200		1,51,200	

The Board of Directors of the Company at its meeting held on February 11, 2026 has approved the Basis of Allocation of Equity Shares as approved by the Designated Stock Exchange viz. NSE and has authorized the corporate action for issue of the Equity Shares to various successful applicants. The CAN-cum-allotment advices and/or notices will forward to the email id's and address of the Applicants as registered with the depositories / as filled in the application form on or before February 11, 2026. Further, the instructions to Self-Certified Syndicate Banks for unblocking the amount will process on or prior to February 11, 2026. In case the same is not received within ten days, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on the NSE Emerge within Three working days from the date of the closure of the issue.

CORRIGENDUM TO THE PROSPECTUS FILED WITH REGISTRAR OF COMPANIES, AHMEDABAD ON FEBRUARY 11, 2026

This Corrigendum is with reference to the Prospectus filed on February 11, 2026. In this regard, please note the following:

- Number of locked in shares and as a % total share held by Promoters and Promoter Group as disclosed on page 86 of Prospectus should be read as 71,10,500 (89.88%), instead of being stated as Zero.
- Number of locked in shares and as a % total share held by Public as disclosed on page 86 of Prospectus should be read as 8,00,500 (10.12%), instead of being stated as Zero.

All capitalized terms used in this Corrigendum to the Prospectus and not specifically defined shall have the same meaning as ascribed to them in the Prospectus dated February 11, 2026.

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the issue, BIGSHARE SERVICES PRIVATE LIMITED at www.bigshareonline.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole applicants, serial number of the Bid cum Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

Bigshare Services Pvt. Ltd.

BIGSHARE SERVICES PRIVATE LIMITED

Office No. S6-2, 6th Floor Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves, road, Andheri (East), Mumbai-400 093.

Tel. No.: 022 - 6263 8200 | E-mail: ipo@bigshareonline.com | Investors Grievance e-mail: investor@bigshareonline.com

Website: www.bigshareonline.com | Contact Person: Mr. Sagar Pathare | SEBI Registration No.: INR000001385

FOR BIOPOL CHEMICALS LIMITED

Sd/-

Santanu Sarkar

Chairman and Managing Director

DIN: 01245213

Date: February 12, 2026

Place: Ahmedabad

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF BIOPOL CHEMICALS LIMITED.

Biopol Chemicals Limited is proposing, subject to market conditions, public issue of its equity shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad. The Prospectus is available on the website of SEBI at www.sebi.gov.in, the website of the Book Running Lead Manager at www.shcapi.com website of the NSE at <https://www.nseindia.com> and website of Issuer Company at <https://biopolchemicals.com/>. Investors should note that investment in Equity Shares involves a high degree of risk. For details, investors shall refer to and rely on the Prospectus including the section titled "Risk Factors" beginning on page 30 of the Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the US Securities Act (the "Securities Act") or any state securities law in United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in the Regulation S under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act of 1933.